Nov. 10, 2022—Vanderbilt research describes a new investigational peptide drug that can penetrate immune and nonimmune cells, and block inflammatory signaling in a preclinical model of atopic dermatitis — eczema.
Nov. 10, 2022—VUMC has begun enrolling patients with asthma in a clinical trial of a novel treatment: a medication approved to treat diabetes and obesity.
Nov. 8, 2022—Vanderbilt researchers found that a protein with roles in innate immunity worsens memory at baseline in carriers of APOE-e4, the strongest genetic risk factor for Alzheimer’s disease, further implicating neuroinflammation in cognitive decline.
Nov. 4, 2022—A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.
Nov. 3, 2022—A team at Case Western Reserve University and Vanderbilt University Medical Center has determined with atomic-level precision how two established drugs bind to and alter the conformation of a cell membrane transporter protein called NKCC1, shutting down its activity.
Nov. 3, 2022—A new Master of Imaging Science program at Vanderbilt will immerse students in the full spectrum of biomedical imaging and provide hands-on clinical and research experience.
Nov. 3, 2022—The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.
Oct. 28, 2022—Fernando Elijovich, MD, professor of Medicine in the Division of Clinical Pharmacology at Vanderbilt University Medical Center, died in Nashville on Oct. 21. He was 77.
Oct. 27, 2022—The 2022 Vanderbilt Translational Research Forum exemplified the range of studies conducted at Vanderbilt University Medical Center that are translating scientific discovery into clinical practice.